Correction to “Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”
{"title":"Correction to “Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”","authors":"","doi":"10.1002/cai2.69","DOIUrl":null,"url":null,"abstract":"<p>Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation.2022;1-5.</p><p>In the funding information, the Grant/Award Number of National Nature Science Foundation of China was incorrect. The Grant/Award Number should be “82103634”.</p><p>We apologize for this error.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 4","pages":"318"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.69","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation.2022;1-5.
In the funding information, the Grant/Award Number of National Nature Science Foundation of China was incorrect. The Grant/Award Number should be “82103634”.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
